Company's Liver Cancer Drug Candidate IP Portfolio strengthened
Company provides operational update on strategic opportunities
NEW YORK, April 14, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – has received a patent in the United States and a notice of allowance in Europe, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market and has received Orphan Drug designation from the FDA.
Read more at prnewswire.com
/Nike%2C%20Inc_%20swish%20by-%20Tartezy%20via%20Shutterstock.jpg)
/Server%20racks%20by%20dotshock%20via%20Shutterstock.jpg)
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)